Hot TopicHereditary prostate cancer – Primetime for genetic testing?
Introduction
Prostate cancer (PCa) is the most prevalent cancer in men and one of the predominant causes of death among men in European countries [1]. While most PCa remain localized, a subset will be aggressive, leading to metastasis formation associated with significant morbidity and mortality. Thus, one major issue in PCa research is to early detect those patients who are likely to harbor an aggressive variant of PCa at young age importantly needing an active anti-cancer treatment.
Large epidemiological studies described that family history is an important risk factor for PCa incidence hence suggesting a genetic component. Genome wide association studies identified around 100 susceptibility loci that contribute to the risk of PCa development and it has been postulated that these loci account for up to 38.9% of the familial risk for PCa [2], [3]. According to current guidelines, positive family history is defined as three or more relatives with PCa, or at least two relatives who have developed early-onset PCa defined as diagnosis at age of 55 or less [4], [5].
Besides the hereditary PCa incidence component, genetic alterations in deoxyribonucleic acid (DNA) repair systems are found in 20% of metastatic castration resistant PCa (mCRPC) patients and emerging data suggest that they may predict therapeutic responses to developing therapies like Poly-ADP-Ribose-Polymerase (PARP) inhibition or immunotherapy leading to improved treatment strategies [6].
In the present review article, we provide an overview about the epidemiology and the genetic basis of PCa predisposition and critically discuss the significance and consequence in the clinical routine. In addition, we give an overview about genetic tests and report latest findings from ongoing clinical studies. Lastly we discuss the impact of genetic testing in personalized medicine in mCRPC.
Section snippets
Epidemiology
Familial history is a well-established risk factor for the development of PCa. Approximately 10–15% of men with PCa have at least one relative who is also affected by PCa. Large epidemiologic studies have demonstrated that men who have a their first-degree relative (father and/or brother) with PCa are at increased risk of developing the disease [7], [8], [9], [10]. Data from more than heterozygous and homozygous twins showed a PCa heritability index of varying from 42 to 58% depending on the
Association of prostate cancer with hereditary cancers
Several epidemiological studies have demonstrated that an association of prostate and breast cancer can be present in certain families. The Breast Cancer Linkage Consortium evaluated 173 breast/ovarian families with a BReast CAncer Gene (BRCA2) mutation and showed a significantly increased risk for PCa (RR = 4.65). This risk was considered even higher before age of 65 (RR = 7.33) with an estimated cumulative incidence of 7.5%–33%, depending on the population used as reference. Statistically
Germline mutation/alterations
Generally, the prevalence of inherited alterations in DNA-repair genes in healthy men and in localized PCa unselected for genetic background is relatively low with a percentage of 2.7% and 4.6% respectively. A recent milestone study by Pritchard and collaborators including 692 males with metastasized disease demonstrated that 11.8% of them harbored germline mutations in 16 genes [33], [34]. Related to the whole number of mutations, those involving BRCA2 (44%), ataxia teleangiectasia mutated
Genetic screening for hereditary prostate cancer
In general, screening for hereditary PCa can have major clinical implications considering the fact that PCa has a certain degree of heritability even mimicking autosomal dominant pathways [13]. Nevertheless, most PCa occur in a sporadic manner, thus screening for hereditary PCa should be focused on specific clinical scenarios leading to the fact that compared to other tumor entities like breast or colorectal cancer genetic counseling in PCa is still in its infancy [5]. However, is it well
Surveillance strategies for high risk patients after local therapy
A special focus should be set on patients with a confirmed hereditary component in the surveillance after primary local therapy. More than 20 years ago, Kupelian and colleagues reported 3-year rates of freedom from biochemical PSA recurrence (BCR) of 52% and 72% in men with and without a family history of PCa, respectively. The 5-year BCR was 52% for men without a family history of PCa and 29% for men with such a history [78]. Also a recent German study evaluated the difference in clinical
Genetic testing for precision oncology in mCRPC patients
In the past years the treatment landscape of mCRPC expanded leading to the fact that several different drugs like chemotherapeutic agents, or hormonal therapies are approved in the same therapy line claiming for appropriate biomarkers for therapy response [85], [86]. In this context, genetic testing can harbor a major impact on therapy decisions. Some years ago, a multi-institutional integrated sequencing analysis of 150 PCa patients demonstrated that 23% of mCRPC harbor DNA repair pathway
Genetic alterations across ethnicities
Generally, most genetic studies have been performed in European and Asian populations, while studies of genetic susceptibility in African descent populations are limited. However, there are strong hints that genetic etiology differs among population diversity. For example, it has been shown that SNPs that had been previously reported in white or Asian populations were not replicated in Afro-American men [93]. In line with this trial also other GWAS studies did not replicate most of the
Ongoing clinical trials
To identify relevant ongoing trials related to this topic, we searched recruiting and not yet recruiting trials in ClinicalTrials.gov (https://clinicaltrials.gov/ct2/home). The terms “germline”, “hereditary”, or “genetic mutations” were used in association with “prostate cancer”. The following information was abstracted from ClinicalTrials.gov and analyzed: title, sponsor, status, objective, primary and secondary outcomes, and eligibility criteria.
A trial (NCT00959023) led by Institute of
Conclusion
It is well recognized that genetic predisposition represents an important risk factor for PCa development and progression. Various recent studies suggest a hereditary component in 8 to 12% of PCa cases mostly associated with germline mutations or alterations in genes like BRCA1, BRCA2, HOXB13 or DNA MMR genes. Moreover, SNPs and copy number variations are discussed as drivers for PCa development and progression. Early onset of aggressive PCa combined with family members also suffering from PCa
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Declaration of Competing Interest
None regarding the topic of this article.
References (96)
- et al.
EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent
Eur Urol
(2017) - et al.
Integrative clinical genomics of advanced prostate cancer
Cell
(2015) - et al.
Autosomal dominant inheritance of prostate cancer: a confirmatory study
Urology
(2001) - et al.
In Swedish families with hereditary prostate cancer, linkage to the HPC1 locus on chromosome 1q24-25 is restricted to families with early-onset prostate cancer
Am J Hum Genet
(1999) - et al.
Concordance of tumor differentiation among brothers with prostate cancer
Eur Urol
(2012) - et al.
Family history and the risk of prostate cancer
Urology
(2000) - et al.
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene
Am J Hum Genet
(2003) - et al.
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study
Eur Urol
(2014) - et al.
Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer
Eur Urol
(2015) - et al.
Germline Mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death
Eur Urol
(2017)
Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA Mismatch repair gene mutations
Eur Urol
Mismatch repair enzyme expression in primary and castrate resistant prostate cancer
Asian J Urol
The homeodomain protein HOXB13 regulates the cellular response to androgens
Mol Cell
A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk
Eur Urol
Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study
Eur Urol
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial
Eur Urol
Prostate cancer (PCa) risk variants and risk of fatal PCa in the national cancer institute breast and prostate cancer cohort consortium
Eur Urol
Genome abnormalities precede prostate cancer and predict clinical relapse
Am J Pathol
Effect of family history on outcome in German patients treated with radical prostatectomy for clinically localised prostate cancer
Eur J Cancer
Family history of prostate cancer and relapse after definitive external beam radiation therapy
Int J Radiat Oncol Biol Phys
Prostate cancer screening in a new era of genetics
Clin Genitourin Cancer
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer
Eur Urol
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide
Eur Urol
Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
Eur Urol
Cancer statistics, 2016
CA Cancer J Clin
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array
Nat Genet
Screening for familial and hereditary prostate cancer
Int J Cancer
Familial risk and familial survival in prostate cancer
World J Urol
Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands
J Natl Cancer Inst
Age specific and attributable risks of familial prostate carcinoma from the family-cancer database
Cancer
Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland
N Engl J Med
The heritability of prostate cancer in the Nordic Twin Study of Cancer
Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Mendelian inheritance of familial prostate cancer
Proc Natl Acad Sci U S A
Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis
Cancer
Prostate cancer risk prediction based on complete prostate cancer family history
Prostate
Cancer risks in BRCA2 mutation carriers
J Nat Cancer Inst
Cancer risks in BRCA2 families: estimates for sites other than breast and ovary
J Med Genet
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer
J Clin Oncol
Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer
Clin Cancer Res
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program
J Natl Cancer Inst
Cancer Incidence in BRCA1 mutation carriers
J Natl Cancer Inst
Germline BRCA1 mutations increase prostate cancer risk
Br J Cancer
The spectrum of urological malignancy in Lynch syndrome
Fam Cancer
The tumor spectrum in the Lynch syndrome
Fam Cancer
The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome
Int J Cancer
Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis
Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types
Nat Genet
Suggestive genetic linkage to chromosome 11p11.2-q12.2 in hereditary prostate cancer families with primary kidney cancer
Prostate
Cited by (18)
Precision intervention for prostate cancer: Re-evaluating who is at risk
2022, Cancer LettersCitation Excerpt :For example, several germline variants of BRCA1 and BRCA2 have been observed in African American men more frequently than in Caucasian American men [85], associating with disease aggressiveness (see below). Additionally, a novel SNP (rs7918885), localized on chromosomal region 10p14 within an intron of a long non-coding region of the GATA3 gene, has been detected exclusively in African American men [86,87], which is notable since loss of function of GATA3 has been functionally implicated in prostate cancer progression [88]. Therefore, analyses of SNPs may inform on differences in the incidence of aggressive prostate cancer observed in African American men (Fig. 1).
Motivation and family communication in hereditary prostate cancer genetic testing: Survey of patients from a US tertiary medical center
2023, Journal of Genetic CounselingResearch progress of familial hereditary prostate cancer
2023, Chinese Journal of UrologyProgress in prostate cancer prevention
2022, European Journal of Cancer Prevention